Antibody-Drug Conjugates Market Set for Significant Growth as Innovation Transforms Cancer Treatment

The antibody-drug conjugates (ADC) market is expected to experience substantial growth across the seven major markets (7MM) during the forecast period, driven by advances in targeted oncology treatments, expanding clinical applications, and promising pipeline developments. The growing effectiveness of ADCs, particularly when evaluated alongside immune checkpoint inhibitors, is encouraging pharmaceutical companies to invest in research and development. Improvements in antibody engineering, cytotoxic payloads, and linker technologies are further strengthening the potential of ADCs to address unmet medical needs across multiple cancer indications.

Discover which therapies are expected to capture market share through the Antibody-drug Conjugates Market and Competitive Landscape Report - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Market Summary and Key Takeaways

• According to DelveInsight, the antibody-drug conjugates market is anticipated to expand considerably through 2034 as innovative therapies advance and additional treatment indications emerge. ENHERTU generated approximately USD 1.4 billion in US sales in 2023, demonstrating the commercial potential of targeted oncology treatments. The United States also recorded nearly 298,000 incident breast cancer cases in 2023, highlighting the substantial patient population that could benefit from advances in cancer treatment.
• Leading companies developing innovative ADCs include AbbVie, Daiichi Sankyo, Merck, Pfizer, Seagen, AstraZeneca, BioNTech, Duality Biologics, Klus Pharma, Ambrx, Johnson & Johnson Innovative Medicine, GeneQuantum Healthcare (Suzhou), and OnCusp Therapeutics.
• Prominent pipeline candidates include telisotuzumab vedotin (ABBV-399), patritumab deruxtecan (HER3-DXd), ladiratuzumab vedotin, Dato-DXd, BNT323/DB-1303, A166, JNJ-0683 (ARX788), GQ1001, and CUSP06.
• Recent regulatory developments have strengthened the outlook for the ADC market. In February 2025, the FDA granted Fast Track designation to CUSP06, a CDH6-targeting ADC, for platinum-resistant ovarian cancer. In January 2025, the FDA expanded ENHERTU's approval to include adults with hormone receptor-positive, HER2-ultralow advanced breast cancer following endocrine therapy.
• In October 2024, Daiichi Sankyo submitted a supplemental new drug application in Japan for ENHERTU in adults with HER2-low or HER2-ultralow unresectable or recurrent breast cancer. In September 2024, AbbVie submitted a Biologics License Application to the US FDA seeking accelerated approval for telisotuzumab vedotin in previously treated patients with locally advanced or metastatic EGFR wild-type, nonsquamous NSCLC with c-Met protein overexpression. ENHERTU also received US Breakthrough Therapy designation in August 2024 for specified hormone receptor-positive, HER2-low or HER2-ultralow breast cancer.

Antibody-Drug Conjugates Market Dynamics

• ADCs combine the tumor-targeting specificity of monoclonal antibodies with the cell-killing activity of cytotoxic drugs. By recognizing particular antigens expressed on cancer cells, these therapies can deliver potent payloads to tumors while potentially limiting damage to healthy tissues. Their clinical progress across breast cancer, lymphoma, urothelial carcinoma, gastric cancer, and non-small cell lung cancer has expanded treatment options for patients whose disease has progressed following conventional therapies.
• Pharmaceutical companies are investing in research to improve ADC efficacy, safety, and applicability across tumor types. Developments in linker stability, payload potency, antibody selection, and drug-to-antibody ratios are helping researchers optimize therapeutic performance. Collaborations among biotechnology companies, pharmaceutical manufacturers, and contract research organizations are also supporting pipeline development and addressing the technical challenges associated with ADC manufacturing.
• Nevertheless, high production costs, manufacturing complexity, potential drug resistance, patient-selection challenges, and regulatory requirements could constrain market expansion. Continued clinical research and improvements in manufacturing scalability will be important to achieving broader adoption.

Marketed Antibody-Drug Conjugates and Treatment Landscape

• Several ADCs have received regulatory approval, including KADCYLA, ADCETRIS, BESPONSA, MYLOTARG, LUMOXITI, POLIVY, PADCEV, TRODELVY, ENHERTU, BLENREP, ZYNLONTA, TIVDAK, and ELAHERE. MYLOTARG was voluntarily withdrawn from the US market in 2017 following concerns about clinical benefit and safety identified in follow-up trials.
• ENHERTU, developed by AstraZeneca and Daiichi Sankyo, targets HER2 and combines trastuzumab with a topoisomerase I inhibitor payload. Its approved uses include specific HER2-positive breast cancer settings and HER2-mutant NSCLC, with additional indications established through subsequent regulatory decisions.
• ADCETRIS, developed by Seagen and Takeda, targets CD30 and uses monomethyl auristatin E (MMAE) as its cytotoxic payload. Its antibody, linker, and microtubule-disrupting agent work together to deliver treatment to CD30-expressing cells. The therapy is approved for certain lymphoma indications across multiple markets.
• TRODELVY, developed by Gilead Sciences, targets Trop-2 and delivers a topoisomerase inhibitor payload. It is approved for specific treatment settings involving unresectable locally advanced or metastatic triple-negative breast cancer. TRODELVY generated approximately USD 1.06 billion in sales in 2023.

Explore currently marketed treatments through the Antibody-drug Conjugate Drugs resource - https://www.delveinsight.com/sample-request/antibody-drug-conjugate-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Emerging ADC Therapies and Leading Companies

Telisotuzumab vedotin is a c-Met-targeting ADC being investigated for NSCLC. AbbVie has evaluated the candidate in the Phase III TeliMET NSCLC-01 trial. The FDA granted it Breakthrough Therapy designation in January 2022 for certain patients with advanced or metastatic nonsquamous NSCLC characterized by high c-Met overexpression following platinum-based treatment. AbbVie's September 2024 regulatory submission represented another important development in its clinical program.

Patritumab deruxtecan is an investigational HER3-targeting ADC developed using Daiichi Sankyo's DXd technology. It combines a fully human monoclonal antibody with a topoisomerase I inhibitor payload. The FDA granted Breakthrough Therapy designation in December 2021 for specified patients with EGFR-mutated locally advanced or metastatic NSCLC. In October 2023, Daiichi Sankyo and Merck established a global collaboration covering patritumab deruxtecan and two additional DXd candidates. Although the FDA issued a Complete Response Letter in June 2024 concerning its third-line NSCLC application, the Phase III HERTHENA-Lung02 trial met its primary endpoint in September 2024.

Ladiratuzumab vedotin, developed by Seagen, targets LIV-1 and has been investigated in combination with pembrolizumab for advanced triple-negative breast cancer.

Other emerging candidates include Dato-DXd from AstraZeneca and Daiichi Sankyo; BNT323/DB-1303 from BioNTech and Duality Biologics; A166 from Klus Pharma; JNJ-0683 (ARX788) associated with Ambrx and Johnson & Johnson Innovative Medicine; GQ1001 from GeneQuantum Healthcare; and CUSP06 from OnCusp Therapeutics.

Antibody-Drug Conjugates Market Overview and Future Outlook

The future of the ADC market will depend on clinical outcomes, regulatory decisions, commercial uptake, and the ability to expand targeted treatments into additional cancer indications. Continued innovation in payload design, linker technology, and antibody specificity could improve therapeutic precision and help address resistance to existing treatments.

Download the Antibody-drug Conjugates Patient Pool analysis to understand patient trends and future treatment opportunities across the 7MM - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

ADC Epidemiology and Patient Population

DelveInsight's epidemiological analysis estimates that the United States recorded approximately 45,000 incident triple-negative breast cancer cases in 2023. Across the 7MM, incident NSCLC cases reached approximately 531,000 in 2023, with the United States representing the largest patient population, followed by Japan. These populations are expected to evolve during the forecast period, influencing treatment demand and market opportunities.